Clinical Trials Browser

Phase 3 × Carcinoma, Ovarian Epithelial × 1 year × Clear all

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06819007 2026-03-05

DO-01

Phase 3 Recruiting

582 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT06915025 2026-02-27

OVATION-3

Phase 3 Recruiting

500 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05316181 2026-02-12

KOV-HIPEC-02R

Phase 3 Active not recruiting

140 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT07218809 2026-01-16

TREVI-OC-01

Phase 3 Recruiting

1,100 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial

NCT04209855 2025-08-27

MIRASOL

Phase 3 Completed

453 enrolled 18 charts 1 FDA

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT06994195 2025-08-17

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer

Phase 3 Recruiting

384 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT04498117 2025-07-09

FLORA-5

Phase 3 Active not recruiting

615 enrolled

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03522246 2025-06-24

ATHENA

Phase 3 Active not recruiting

1,097 enrolled 26 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

Clinical Trials

KEYNOTE-B96

DO-01

OVATION-3

KOV-HIPEC-02R

TREVI-OC-01

MIRASOL

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer

FLORA-5

ATHENA